The group's principal activities are to discover, develop and commercialize innovative pharmaceuticals for the treatment of neurodegenerative diseases and other neurological and psychiatric disorders. The group is developing family of chemical compounds known as ampakine that enhance the activity of this receptor. The group has been centered on developing products that affect the ampa-type glutamate receptor, a complex of proteins that is involved in most excitatory communication between nerve cells in the human brain.
